Adverum Biotechnologies

Adverum Biotechnologies
Traded as NASDAQ: ADVM
Russell 2000 Component
Website adverum.com

Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL)[1] biotechnology company in the NASDAQ Biotechnology Index that is focused on diseases of the eye.[2] This includes macular degeneration,[3] retinal vein occlusion,[4] diabetic macular edema,[5] and others.[6] The company's only drug in clinical trials, AVA-101, designed to treat macular degeneration, had poor results after initial clinical trials in 2015.[5] In 2016 Avalanche Biotechnologies merged with Annapurna Therapeutics to form Advertum Biotechnologies, Inc.[7]

References

  1. ↑ "Avalanche Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
  2. ↑ "Avalanche Biotechnologies Announces Leadership Transition". www.reuters.com. Retrieved 4 January 2016.
  3. ↑ "Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? - Avalanche Biotechnologies (NASDAQ:AAVL)". Seeking Alpha. Retrieved 4 January 2016.
  4. ↑ Burger, Danielle. "Avalanche Drops as Gene Therapy Data Miss High Expectations". Bloomberg.com.
  5. 1 2 "Update on the latest in business:". WTOP. Tegna Media. Retrieved 4 January 2016.
  6. ↑ Burger, Danielle. "Avalanche drops eye drug trial, takes it back to lab". CNBC.
  7. ↑ "Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies". Global News Wire. 12 May 2016. Retrieved 30 May 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.